Last reviewed · How we verify
Albumin 20% and terlipressin — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Albumin 20% and terlipressin (Albumin 20% and terlipressin) — Amany Mousa Salama Muhammed.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Albumin 20% and terlipressin TARGET | Albumin 20% and terlipressin | Amany Mousa Salama Muhammed | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Albumin 20% and terlipressin CI watch — RSS
- Albumin 20% and terlipressin CI watch — Atom
- Albumin 20% and terlipressin CI watch — JSON
- Albumin 20% and terlipressin alone — RSS
Cite this brief
Drug Landscape (2026). Albumin 20% and terlipressin — Competitive Intelligence Brief. https://druglandscape.com/ci/albumin-20-and-terlipressin. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab